Clinical Trials

LAT-NP-001


Lateral Pharma commenced its first clinical study, LAT-NP-001, in Q1 2019. LAT-NP-001 is a Phase IIa study of the efficacy and safety of twice daily oral administration of 30mg LAT8881 in neuropathic pain.

There were 53 patients with either diabetic peripheral neuropathy or post-herpetic neuralgia randomised to this placebo-controlled, crossover study. Patients were recruited from four sites across Australia and two in the United Kingdom.

Having reached its study target in Q1 2020, the study was closed to recruitment, and results will be available by Q3 2020.

LAT-MIG-001


Lateral Pharma commenced its second clinical study, LAT-MIG-001, in Q3 2019. LAT-MIG-001 is a proof-of-concept Phase IIa study of the efficacy of oral LAT8881 in acute migraine. There were 21 patients with acute migraine randomised to this placebo-controlled, crossover study. Patients were recruited from three sites across Australia. Having reached its study target in Q2 2020, the study was closed to recruitment, and results will be available by Q3 2020.

Future Clinical Trialsl


Lateral will continue to progress its clinical development of LAT8881 in pain. Future trials will be guided by results arising from LAT-NP-001 and LAT-MIG-001, data arising from ongoing preclinical research, and funding and partnering opportunities.